Investment Thesis
Nautilus Biotechnology is a pre-revenue/early-stage company with no reported revenue, significant operating losses (-$1.8M), and substantial net losses (-$14.7M). Operating cash burn of -$13.1M annually against only $14.6M in cash reserves provides limited runway (~1.3 years) with no clear path to profitability. While the balance sheet is debt-free and initially appears strong, the fundamental business model has not demonstrated commercial viability.
Strengths
- Strong balance sheet with $144.4M stockholders' equity and minimal liabilities
- Excellent liquidity position (11.85x current ratio, 11.81x quick ratio) providing near-term operational flexibility
- Zero long-term debt and fully debt-free capital structure
- Modest improvement in EPS (-0.12) showing 16.1% YoY enhancement despite losses
- Operating in high-potential laboratory analytical instruments sector (SIC 3826)
Risks
- No revenue reported - inability to assess commercial viability, product-market fit, or business model sustainability
- Severe cash burn of -$13.1M annually from operations with only ~1.3 years of cash runway remaining
- Persistent and substantial operating losses (-$1.8M) and net losses (-$14.7M) with no profitability trajectory visible
- Negative returns on equity (-10.2%) and assets (-8.3%) indicating value destruction for shareholders
- Pre-revenue or very early-stage commercialization status with unproven ability to generate revenue at scale
Key Metrics to Watch
- Revenue generation and timing of commercial product launches
- Quarterly cash burn rate and cash runway extension milestones
- Progress toward gross margin profitability and operating margin breakeven
- Customer acquisition, pipeline development, and proof-of-concept validations
Financial Metrics
Revenue
N/A
Net Income
-14.7M
EPS (Diluted)
$-0.12
Free Cash Flow
-13.6M
Total Assets
177.8M
Cash
14.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-10.2%
ROA
-8.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
11.85x
Quick Ratio
11.81x
Debt/Equity
0.00x
Debt/Assets
18.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T13:27:35.274236 |
Data as of: 2026-03-31 |
Powered by Claude AI